Dalbavancin: a review for dermatologists

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Medicine

Background:

• Complicated skin and skin structure infections (cSSSI) are often caused by Staphylococcus aureus (SA) and Streptococcus (SC).
• Increasing antibiotic resistance, including methicillin-resistant SA (MRSA) and concerns over vancomycin-resistant SA (VRSA), necessitates new treatment options.
• Dalbavancin is a novel lipoglycopeptide antibiotic developed to improve upon existing glycopeptides like vancomycin.

Purpose of the Study:

• To evaluate the efficacy and safety of dalbavancin for treating complicated skin and skin structure infections (cSSSI).
• To compare dalbavancin's non-inferiority against standard-of-care antibiotics for Gram-positive bacterial SSTIs.

Main Methods:

• Phase-III clinical trials involving over 1,500 patients with skin and soft tissue infections (SSTIs).
• Evaluation of clinical response at 2 weeks post-therapy for dalbavancin compared to linezolid, cefazolin, or vancomycin.
• Assessment of adverse effects associated with dalbavancin treatment.

Main Results:

• Dalbavancin met the primary endpoint of non-inferiority compared to standard treatments.
• The most common adverse effects reported were mild, including headache and pyrexia.
• Once-weekly dalbavancin administration may reduce the need for continuous IV lines, potentially lowering infection rates.

Conclusions:

• Dalbavancin shows promise as an effective treatment for Gram-positive bacterial cSSSI.
• Its favorable side effect profile and convenient dosing schedule may enhance patient management and facilitate transitions to lower levels of care.
• Further evaluation is needed to determine dalbavancin's role relative to vancomycin and other novel agents like linezolid.